Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …

Hepatocellular carcinoma (HCC) is a common cause of cancer‐related death. Sorafenib
prolongs survival of patients with advanced disease and is approved for the systemic …

Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …

Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-
regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important …

Background Multidrug resistance is a major reason for poor treatment results in advanced
hepatoblastoma (HB). Several alternative treatment options are currently under investigation …

Background The outcomes for patients with advanced hepatocellular carcinoma (HCC)
receiving sorafenib are far from satisfactory because of treatment resistance to sorafenib …

Background The multikinase inhibitor sorafenib inhibits angiogenesis and tumor cell
proliferation. Sorafenib targets signaling pathways involved in liver regeneration. Previous …

To suppress the invasion of hepatocellular carcinoma (HCC) cells into surrounding
connective tissues during metastasis, we investigated the usefulness of sorafenib. In order to …